MHRA and partners unite to reaffirm Rx weight-loss meds advertising rules
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA), in partnership with the Advertising Standards Authority (ASA) and General Pharmaceutical Council (GPhC), has this week jointly released an updated Enforce Notice, to reiterate the rules around the advertising of prescription-only medicines (POMs) used for weight management.
The GLP-1 agonists weight loss drugs market in UK is expected to reach a projected revenue of $715.1 million by 2030, up from $222.4 million in 2024. A compound annual growth rate of 17.7% is expected of UK GLP-1 agonists weight loss drugs market from 2025 to 2030, according to Grand View Horizon.
The updated notice is directed at businesses, primarily pharmacies, that make these medicines available to the public and provides important clarity on the kinds of claims and images in an ad that are likely to break the rules.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze